title: [Neurospecific proteins and autoantibodies in serum of patients with acute ischemic stroke].
abstract: Neurospecific enolase (NSE), gliofibrillar acid protein (GFAP), S100 protein and autoantibodies (AAB) to these proteins have been measured in the blood of 42 patients with acute ischemic stroke. Concentrations of all parameters we re increased in patients compared to the control group. There were a positive correlations between contents of AAB to GFAP and AAB to NSE (r = 0.470; p < 0.015) and a reverse correlation between concentrations of NSE and AAT to NSE (r = -0.301; p < 0.028). A study of the relationship between intensity of neurological deficit and AAB concentrations revealed the reverse correlation between the level of AAB to GFAP and scores on the European Stroke scale (ESS) (r = -0.509; p < 0.009) at the first day of ischemic stroke, i.e. in patients with marked neurological deficit (low scores on ESS) the levels of AAB to GFAP were higher. The higher concentration of AAB to NSE was found for the satisfactory rehabilitation, while the neurological deficit was significantly more severe (p = 0.034) at the AAT to NSE level less than 1.19 relative units. The more complete rehabilitation to the 21st day was reverse-correlated to the NSE concentration (r = -0.309; p < 0.026). There was the positive correlation between the restoration of lost functions (the increase of ESS scores from the 1st to 21st days) and levels of AAB to GFAP (r = 0.505; p < 0.023) and AAB to S100 (r = 0.450; p < 0.046).
authors.forename: P R
authors.initials: PR
authors.lastname: Kamchatov
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Ruleva
authors.forename: S F
authors.initials: SF
authors.lastname: Dugin
authors.forename: L I
authors.initials: LI
authors.lastname: Buriachkovskaia
authors.forename: A V
authors.initials: AV
authors.lastname: Chugunov
authors.forename: N A
authors.initials: NA
authors.lastname: Mikhaĭlova
authors.forename: D A
authors.initials: DA
authors.lastname: Basse
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002545:Brain Ischemia / Q000097:blood* / Q000276:immunology / Q000534:rehabilitation; D004185:Disability Evaluation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D005904:Glial Fibrillary Acidic Protein / Q000097:blood* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010751:Phosphopyruvate Hydratase / Q000097:blood* / Q000276:immunology; D011379:Prognosis; D020127:Recovery of Function; D009418:S100 Proteins / Q000097:blood* / Q000276:immunology; D012720:Severity of Illness Index
chemical_list: D001323:Autoantibodies; D015415:Biomarkers; D005904:Glial Fibrillary Acidic Protein; D009418:S100 Proteins; D010751:Phosphopyruvate Hydratase